Clinical Trials Logo

Radiodermatitis clinical trials

View clinical trials related to Radiodermatitis.

Filter by:

NCT ID: NCT04239560 Completed - Radiodermatitis Clinical Trials

Preventive Effect of Boron-based Gel on Radiation Dermatitis

boron_gel
Start date: February 4, 2019
Phase: Phase 3
Study type: Interventional

Preventive Effect of Boron-based Gel on Radiation Dermatitis

NCT ID: NCT04238728 Completed - Clinical trials for Radiation Dermatitis

Silverlon to Reduce Radiation Dermatitis

Start date: August 31, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to see if a silver-nylon dressing (Silverlon®, Argentum Medical) is useful for the prevention or treatment of radiation dermatitis in patients receiving radiation therapy to the breast.

NCT ID: NCT04173247 Completed - Clinical trials for Head and Neck Cancer

Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy

Start date: July 27, 2020
Phase: N/A
Study type: Interventional

This is a single site, randomized, open-label comparison pilot study to assess the feasibility and effectiveness of KeraStat Cream compared with routine skin care (RSC) in managing radiotherapy-induced early adverse skin reaction (EASR) in patients undergoing radiotherapy to the head and/or neck. Hypothesis: The use of KeraStat Cream in patients receiving radiotherapy for head and neck is feasible, tolerable, and reduces the severity of early adverse skin reaction in the treated region of interest.

NCT ID: NCT04059809 Completed - Breast Cancer Clinical Trials

Photobiomodulation for Breast Cancer Radiodermatitis

Start date: September 26, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

A prospective single blind controlled randomized trial to evaluate the superiority of photobiomodulation (PBM) using LED-therapy in reducing the prevalence of radiodermatitis in breast cancer compared to usual local care.

NCT ID: NCT04013711 Completed - Clinical trials for Radiotherapy Side Effect

Thermal Imaging to Evaluate Skin Toxicity From Radiotherapy

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

A significant proportion of patients treated with whole-breast or head and neck radiotherapy will experience skin toxicity, i.e. skin dermatitis, which may lead to erythema, dry desquamation and wet desquamation. It is hypothesized that quantitative thermal imaging can be used to measure radiation-induced skin toxicity.

NCT ID: NCT03988556 Completed - Clinical trials for Radiation Dermatitis

Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis

SafePBM
Start date: July 4, 2019
Phase: N/A
Study type: Interventional

The main objective of the present study is to investigate the feasibility, safety and tolerability of CareMin650 in patients with 1) head & neck cancer at high risk of or suffering from oral mucositis and/or radiation dermatitis due to the administration of radiotherapy with or without chemotherapy with or without targeted therapy, 2) breast cancer at high risk of or suffering from radiation dermatitis due to the administration of radiotherapy.

NCT ID: NCT03941665 Completed - Clinical trials for Radiation Dermatitis

Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients

Start date: March 25, 2019
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the effect of Gelronate gel, NaHA based product (medical device for topical application) vs. Aloevera gel, in prevention or minimizing of radiation induced skin reaction in breast cancer patients

NCT ID: NCT03924011 Completed - Breast Cancer Clinical Trials

Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy

LABRA
Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Radiodermatitis (RD), an inflammatory skin reaction, occurs in more than 90 percent of cancer patients treated with radiotherapy (RT). This is the result of the radiation causing damage to the epidermal basal skin stem cells. Based on the severity of the skin symptoms, acute RD can be categorized into four grades ranging from red and dry skin to moist desquamation, necrosis, and eventually ulceration. Acute RD can be distressing, negatively influencing the patients' quality of life (QOL). In cases of severe RD, RT might be interrupted, affecting the treatment outcome. Currently, there is no generally accepted treatment available for RD. As such, the standard skincare treatment is hospital dependent. Photobiomodulation therapy (PBMT) can offer a solution, since the therapeutic use of (infra)red light induces photochemical reactions in the target cells, stimulating repair and healing processes, and reducing pain and inflammation. Previous studies using PBMT to prevent RD showed promising results. However, these beneficial results need to be validated in a larger breast cancer patient population receiving an alternative RT regimen. The study hypothesizes that PBMT is a safe and effective strategy to prevent worsening of acute RD grade two or higher in breast cancer patients undergoing RT. The primary objective is to measure the degree of acute RD to detect changes during and after RT. Second, the patients' QOL and pain will be assessed. Finally, the third objective is to evaluate the safety of PBMT. The results of this project will support the implementation of PBMT into the standard RD skincare program.

NCT ID: NCT03910595 Completed - Breast Cancer Clinical Trials

Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients

Start date: March 14, 2019
Phase: N/A
Study type: Interventional

In patients undergoing adjuvant radiotherapy for breast cancer, radiation-induced skin toxicities are a common occurrence and adversely impact patients' quality of life (QOL). In the last decade, there have been no significant advances in preventing or treating radiation-induced skin toxicities. Recently, a phase III randomized trial by Herst et al. (n=78) in New Zealand showed that the prophylactic use of Mepitel Film reduced skin reaction severity by 92% compared to skin treated only with aqueous cream. Mepitel film has not been widely adopted in North America. To validate the efficacy of the film and guide the development of a larger multi-centre phase II study, a pilot study testing the efficacy of the film is proposed. In the study, 30 patients will have the film applied on their breast for the duration of radiation treatment and their skin reactions will be assessed throughout the treatment and after the treatment. The investigators hypothesize that the severity and incidence rates of skin reactions for patients using Mepitel film will be lower when compared to real world data from our centre, and that cosmetic outcomes will be improved with the film.

NCT ID: NCT03883828 Completed - Clinical trials for Radiation Dermatitis

Bacterial Decolonization to Prevent Radiation Dermatitis

Start date: June 3, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.